# Bluejay Therapeutics

**Canonical:** https://apis.io/providers/bluejay-therapeutics/  
**Website:** https://bluejaytx.com/  
**APIs profiled:** 6

Bluejay Therapeutics, Inc. was a clinical-stage biopharmaceutical company headquartered in Redwood City, California, developing treatments for viral hepatitis and liver disease. Its lead asset, brelovitug (BJT-778), is an investigational monoclonal antibody targeting the surface antigen shared by the hepatitis D and hepatitis B viruses; it received U.S. FDA Breakthrough Therapy designation for chronic hepatitis delta and reported a 100% virologic response at week 48 in its Phase 2 monotherapy study before entering the AZURE-2 global Phase 3 trial. The company also advanced a proprietary TLR9 agonist (cavrotolimod), a liver-targeted HBV transcript inhibitor (BJT-628) and a liver-targeted fatty acid synthase inhibitor (BJT-188) toward a combination regimen aimed at functional cure of chronic hepatitis B. Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics in December 2025 and completed the acquisition on 26 January 2026; the corporate site now serves a single acquisition notice redirecting readers to mirumpharma.com. Bluejay Therapeutics never ran a developer program — no product API, no developer portal, no API documentation, no SDKs, no GitHub organisation and no package-registry presence. The only machine-readable surface reachable without credentials is the WordPress REST content API behind bluejaytx.com, catalogued here. That surface is notable for outliving the web site it belongs to: the marketing page tree was deleted in the teardown, but the REST API and the post archive still serve all 35 press releases and publication notices from 2021 through 2025 with full text.

## Kin Score — 26.1 / 100 (emerging)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 26.1).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 58.0 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 14.7 |
| Commercial Clarity | 0.0 |

Regulatory layer — **Health**: 21.3 (matched via tags).

## Agent readiness — 30.0 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (6)

- **Bluejay Therapeutics Content API** — Posts, pages and cross-content search.
- **Bluejay Therapeutics Discovery API** — Route index and namespace discovery documents.
- **Bluejay Therapeutics Embed API** — oEmbed 1.0 provider endpoint.
- **Bluejay Therapeutics Empty Collections API** — Registered collections that answer 200 anonymously but currently hold no items.
- **Bluejay Therapeutics Media API** — The site media library.
- **Bluejay Therapeutics Taxonomy API** — Categories, tags and taxonomy/type/status registries.

## Security (2)

- **Bluejay Therapeutics Authentication** — 1 scheme
- **Bluejay Therapeutics Domain Security** — TLSv1.3 · DNSSEC · DMARC

## Tags

Company, biopharmaceuticals, pharmaceuticals, life-sciences, hepatology, infectious-disease, clinical-trials, drug-development, monoclonal-antibodies, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/bluejay-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.